TransMedics Group, Inc. (NASDAQ:TMDX – Get Free Report) has been assigned an average recommendation of “Moderate Buy” from the nine analysts that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $171.44.
TMDX has been the topic of several research reports. Canaccord Genuity Group raised their price objective on TransMedics Group from $117.00 to $169.00 and gave the stock a “buy” rating in a report on Thursday, August 1st. Stephens raised their price target on TransMedics Group from $151.00 to $178.00 and gave the stock an “overweight” rating in a research note on Friday, August 2nd. Cantor Fitzgerald began coverage on TransMedics Group in a research note on Thursday, June 6th. They issued an “overweight” rating and a $161.00 price objective for the company. Needham & Company LLC assumed coverage on shares of TransMedics Group in a research report on Wednesday, August 21st. They set a “buy” rating and a $208.00 target price on the stock. Finally, Oppenheimer lifted their target price on shares of TransMedics Group from $125.00 to $200.00 and gave the company an “outperform” rating in a report on Thursday, August 1st.
View Our Latest Analysis on TMDX
Insider Buying and Selling
Institutional Trading of TransMedics Group
A number of institutional investors have recently modified their holdings of TMDX. Sanctuary Advisors LLC acquired a new stake in TransMedics Group in the second quarter valued at $372,000. Teachers Retirement System of The State of Kentucky purchased a new position in shares of TransMedics Group in the 2nd quarter valued at about $420,000. NewEdge Advisors LLC lifted its stake in shares of TransMedics Group by 26.0% in the second quarter. NewEdge Advisors LLC now owns 10,372 shares of the company’s stock valued at $1,562,000 after purchasing an additional 2,140 shares during the period. Creative Planning boosted its holdings in TransMedics Group by 78.3% during the second quarter. Creative Planning now owns 9,173 shares of the company’s stock worth $1,382,000 after buying an additional 4,027 shares in the last quarter. Finally, Algert Global LLC acquired a new position in TransMedics Group during the second quarter worth about $2,685,000. 99.67% of the stock is currently owned by hedge funds and other institutional investors.
TransMedics Group Price Performance
TMDX stock opened at $165.00 on Friday. The stock has a market cap of $5.43 billion, a price-to-earnings ratio of -485.29 and a beta of 1.99. TransMedics Group has a fifty-two week low of $36.42 and a fifty-two week high of $177.37. The company has a quick ratio of 8.48, a current ratio of 9.37 and a debt-to-equity ratio of 2.67. The business has a 50 day moving average price of $155.65 and a 200 day moving average price of $129.31.
TransMedics Group (NASDAQ:TMDX – Get Free Report) last issued its earnings results on Wednesday, July 31st. The company reported $0.35 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.21 by $0.14. The business had revenue of $114.30 million during the quarter, compared to analysts’ expectations of $98.84 million. TransMedics Group had a net margin of 0.84% and a return on equity of 15.98%. The company’s revenue for the quarter was up 117.7% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.03) EPS. Equities research analysts anticipate that TransMedics Group will post 1.23 earnings per share for the current fiscal year.
TransMedics Group Company Profile
TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.
Further Reading
- Five stocks we like better than TransMedics Group
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- Take Advantage of Village Farms Stock as Cannabis Market Evolves
- What Are Dividends? Buy the Best Dividend Stocks
- MarketBeat Week in Review – 9/16 – 9/20
- What does consumer price index measure?
- Don’t Miss These 3 Retail Stocks for Fall Gains
Receive News & Ratings for TransMedics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransMedics Group and related companies with MarketBeat.com's FREE daily email newsletter.